Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia

doi:10.1042/BJ20061040

Journal List > Biochem J > v.402(Pt 2); Mar 1, 2007

Biochem J. 2007 March 1; 402(Pt 2): 349–357.

Published online 2007 February 12. Prepublished online 2006 November 15. doi: 10.1042/BJ20061040.

PMCID: PMC1798429

Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia

Takashi Murayama,^*¹ Toshiharu Oba,^† Hiroshi Hara,^‡ Kikuo Wakebe,^‡ Noriaki Ikemoto,^§^¶ and Yasuo Ogawa^*

*Department of Pharmacology, Juntendo University School of Medicine, Tokyo 113-8421, Japan

†Department of Regulatory Cell Physiology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan

‡Miyazaki Station National Livestock Breeding Center, Miyazaki, Japan

§Boston Biomedical Research Institute, Watertown, MA 02472, U.S.A.

¶Harvard Medical School, Boston, MA 02115, U.S.A.

¹To whom correspondence should be addressed (email takashim/at/med.juntendo.ac.jp).

Received July 10, 2006; Revised November 3, 2006; Accepted November 15, 2006.

This article has been cited by other articles in PMC.

Abstract

We have demonstrated recently that CICR (Ca²⁺-induced Ca²⁺ release) activity of RyR1 (ryanodine receptor 1) is held to a low level in mammalian skeletal muscle (‘suppression’ of the channel) and that this is largely caused by the interdomain interaction within RyR1 [Murayama, Oba, Kobayashi, Ikemoto and Ogawa (2005) Am. J. Physiol. Cell Physiol. 288, C1222–C1230]. To test the hypothesis that aberration of this suppression mechanism is involved in the development of channel dysfunctions in MH (malignant hyperthermia), we investigated properties of the RyR1 channels from normal and MHS (MH-susceptible) pig skeletal muscles with an Arg⁶¹⁵→Cys mutation using [³H]ryanodine binding, single-channel recordings and SR (sarcoplasmic reticulum) Ca²⁺ release. The RyR1 channels from MHS muscle (RyR1_MHS) showed enhanced CICR activity compared with those from the normal muscle (RyR1_N), although there was little or no difference in the sensitivity to several ligands tested (Ca²⁺, Mg²⁺ and adenine nucleotide), nor in the FKBP12 (FK506-binding protein 12) regulation. DP4, a domain peptide matching the Leu²⁴⁴²–Pro²⁴⁷⁷ region of RyR1 which was reported to activate the Ca²⁺ channel by weakening the interdomain interaction, activated the RyR1_N channel in a concentration-dependent manner, and the highest activity of the affected channel reached a level comparable with that of the RyR1_MHS channel with no added peptide. The addition of DP4 to the RyR1_MHS channel produced virtually no further effect on the channel activity. These results suggest that stimulation of the RyR1_MHS channel caused by affected inter-domain interaction between regions 1 and 2 is an underlying mechanism for dysfunction of Ca²⁺ homoeostasis seen in the MH phenotype.

Keywords: calcium release channel, malignant hyperthermia, ryanodine receptor type 1, sarcoplasmic reticulum, skeletal muscle

Abbreviations: AMPPCP, β,γ-methylene adenosine triphosphate, CICR, Ca²⁺-induced Ca²⁺ release, DICR, depolarization-induced Ca²⁺ release, FKBP, FK506-binding protein, MH, malignant hyperthermia, MHS, MH-susceptible, Mopso, 3-(N-morpholino)-2-hydroxypropanesulfonic acid, P_o, mean open probability, RyR, ryanodine receptor, SR, sarcoplasmic reticulum

INTRODUCTION

In skeletal muscle, RyR1 (type 1 ryanodine receptor) is a Ca²⁺ release channel of the SR (sarcoplasmic reticulum) and plays an important role in excitation–contraction coupling [1,2]. Ca²⁺ release through the RyR1 channel can be activated by two distinct modes: DICR (depolarization-induced Ca²⁺ release) and CICR (Ca²⁺-induced Ca²⁺ release). DICR is triggered by conformational change of the dihydropyridine receptor upon depolarization of the T tubular membrane [3,4]. CICR is a ligand-gated mode in which Ca²⁺ itself regulates the channel activity: micromolar or more concentrations of Ca²⁺ activate the channel, whereas millimolar Ca²⁺ concentrations inactivate it [5]. In addition, ‘gain’ is an important determinant for the CICR activity which determines the maximal activity under respective conditions independently of Ca²⁺-sensitivity [6,7]. The gain is affected by various CICR modulators, e.g. adenine nucleotides increase the gain, whereas procaine decreases it.

RyR1 is the major target for MH (malignant hyperthermia), an autosomal-dominant pharmacogenetic disorder triggered by volatile anaesthetics such as halothane, and to date more than 80 mutations have been identified in RyR1 of MH patients [8,9]. An enhanced CICR activity with higher sensitivity to caffeine or halothane was consistently reported in MH-mutated RyR1 [10]. Sensitization of DICR activity was also reported [11,12]. Thus it is widely accepted that MH mutations cause hyperactivation/hypersensitization of the Ca²⁺ release channel, resulting in abnormal Ca²⁺ homoeostasis in skeletal muscle. However, it remains to be elucidated how these mutations cause such dysfunctions in the Ca²⁺ release channel. Most known MH mutations are located in one of three ‘hot spots’, i.e. the N-terminal region (region 1, amino acids 35–614), the central region (region 2, amino acids 2163–2458) and the C-terminal transmembrane region (region 3, amino acids 3916–4973). Ikemoto and Yamamoto [13] have found that several short synthetic peptides corresponding to sequences within regions 1 and 2 of RyR1 activate the Ca²⁺ release channel. Among them, a 36-residue peptide corresponding to the Leu²⁴⁴²–Pro²⁴⁷⁷ region, designated DP4, potently activated RyR1 [14–16]. Importantly, introduction of an MH mutation in DP4 (DP4-mut, mimicking an Arg²⁴⁵⁸→Cys mutation) totally abolished these effects. Similar activation was induced by site-specific antibodies directed to the N-terminal (region 1) and the central (region 2) domains [17]. Further studies demonstrated that DP4 binds with the N-terminal portion of region 1 [18], and causes unzipping between regions 1 and 2 [19]. On the basis of these findings, it was hypothesized (i) that the two domains of RyR1 normally interact with each other to stabilize the closed state of the channel, (ii) that MH mutation in either domain weakens this interdomain interaction, resulting in destabilization of the channel, which erroneously increases channel activity, and (iii) that exogenous domain peptides (e.g. DP4) mimic the phenotype of MH mutation by competitively interfering with the interdomain interaction [13].

We have shown previously that [³H]ryanodine binding to RyR1 is significantly lower than that of RyR3 (type 3 ryanodine receptor), another isoform in skeletal muscle, suggesting that the CICR activity of RyR1 is ‘suppressed’ to a low level in skeletal muscle SR [20–22]. This suppression is attributed to a reduced gain of the CICR without significant changes in the sensitivity to known CICR ligands and drugs (e.g. Ca²⁺, Mg²⁺, adenine nucleotides and caffeine) [20,21]. The suppression effect is produced by two independent factors: protein-bound FKBP12 (FK506-binding protein 12) and the interdomain interaction within RyR1; the latter mechanism accounts for ~70% of the suppression [21,22]. We claimed that suppression of the RyR1 channel is important in Ca²⁺ homoeostasis in skeletal muscle, and aberration in this mechanism thus causes dysfunctions of RyR1 channels as seen in some muscle diseases such as MH. However, this remains to be elucidated.

To test the hypothesis, in the present study, we investigated the properties of the RyR1 channel with the SR vesicles isolated from skeletal muscles of normal and MHS (MH-susceptible) pigs using [³H]ryanodine binding assays, single-channel current recordings and caffeine-induced Ca²⁺ release measurements. MHS pigs carry an Arg⁶¹⁵→Cys mutation in the RyR1 and are known to be an excellent animal model for human MH [10]. Here we report that affecting the N-terminal and central domain interactions by the aforementioned domain peptide (DP4) produced a significant channel activation (i.e. removal of suppression) in the RyR1 from normal pigs (RyR1_N), but it produced no further effect on the channel function of the RyR1 from MHS pigs (RyR1_MHS). These results suggest that the suppression is largely impaired in RyR1_MHS in comparison with RyR1_N, and that this impaired suppression is caused primarily by the affected interdomain interaction within the RyR1_MHS.

EXPERIMENTAL

Materials

Peptides (DP4 and DP4-mut) were synthesized on a synthesizer (Applied Biosystems model 431 A) employing Fmoc (fluoren-9-ylmethoxycarbonyl) as the α-amino-protecting group and purified by reverse-phase HPLC [14]. [³H]Ryanodine (50–60 Ci/mmol) was purchased from NEN Life Science Products. All other reagents were of analytical grade.

Animals and preparation of SR vesicles

All of the experiments were carried out in accordance with Juntendo University Ethics Committee guidelines. Homozygous MHS pigs for the RyR1 Arg⁶¹⁵→Cys mutation and homozygous normal pigs were obtained by breeding heterozygous parent pigs that had been maintained in the Miyazaki Station, National Livestock Breeding Center (Miyazaki, Japan). Animals used for the experiments were 2-month-old littermates that had been tested for the presence of the normal and MHS RyR1 alleles. Animals were killed using an intravenous injection of pentobarbital overdose. Back muscles were excised immediately and frozen rapidly in liquid nitrogen. Crude SR vesicles were prepared from the muscle by the method of Murayama and Ogawa [23] and terminal cisterna-rich fractions were obtained by sucrose-density-gradient ultracentrifugation [21]. The vesicles were quickly frozen with liquid nitrogen, and stored at −80 °C until use.

[³H]Ryanodine binding

The [³H]ryanodine binding assay was carried out as described previously [22]. Briefly, the SR vesicles (100 μg of protein) were incubated with 8.5 nM [³H]ryanodine for 5 h at 25 °C in a 100 μl solution containing 0.17 M NaCl, 20 mM Mopso [3-(N-morpholino)-2-hydroxypropanesulfonic acid], pH 6.8, 2 mM dithiothreitol, 1 mM AMPPCP (β,γ-methylene adenosine triphosphate) and various concentrations of Ca²⁺ buffered with 10 mM EGTA (calculated using the value of 8.79×10⁵ M⁻¹ as the apparent binding constant for Ca²⁺ of EGTA [24]) unless otherwise indicated. The protein-bound [³H]ryanodine was separated by filtering through polyethyleneimine-treated Whatman GF/B filters. Non-specific radioactivity was determined in the presence of 20 μM unlabelled ryanodine. The [³H]ryanodine binding data (B) obtained under various assay conditions in the presence of a fixed concentration of [³H]ryanodine (8.5 nM throughout these experiments) were expressed in relative values to the maximal binding sites for the ligand (B_max); thus B/B_max reflected an apparent averaged activity of individual Ca²⁺ release channels. B_max was determined on the Scatchard plot for [³H]ryanodine binding in a medium containing 1 M NaCl and various concentrations of [³H]ryanodine. Apparent dissociation constants for Ca²⁺ of the Ca²⁺-activation site (K_A,Ca) and Ca²⁺-inactivation site (K_I,Ca) and those for Mg²⁺ (K_A,Mg and K_I,Mg) were estimated according to the method of Murayama et al. [25].

Single-channel recordings

Single-channel recordings were carried out as described previously with CHAPS-solubilized SR protein as a material [26,27]. Lipid bilayers consisting of a mixture of L-α-phosphatidylethanolamine, L-α-phosphatidyl-L-serine and L-α-phosphatidylcholine (5:3:2 by weight) in n-decane (40 mg/ml) were formed across a hole of ~250 μm in diameter in a polystyrene partition separating cis and trans chambers. Channel currents were recorded in symmetrical solutions of 250 mM caesium methanesulfonate buffered at pH 6.8 with 20 mM Hepes/Tris at the holding potential of −40 mV (cis). Experiments were carried out at 18–22 °C. Bilayers containing only a single channel were used for analysis. Channel currents amplified by an Axopatch 1D patch clamp amplifier (Axon Instruments) were filtered at 1 kHz using an eight-pole low-pass Bessel filter and collected at 5 kHz for analysis. Mean open probability (P_o) was calculated from the records of duration >2 min by 50% threshold analysis using pClamp (version 6.0.4) software.

Ca²⁺ release measurements

Ca²⁺ release from the isolated SR vesicles was fluorometrically measured by monitoring free Ca²⁺ concentration in the solution [22]. Briefly, SR vesicles (80 μg) were incubated at 30 °C in a fluorimeter cuvette containing 400 μl of 0.17 M KCl, 20 mM Mopso, pH 6.8, 1 mM MgCl₂, 5 mM potassium phosphate, 10 mM phosphocreatine, 2 units/ml of creatine kinase and 2 μM fura 2. Fluorescence was measured in a Hitachi F-4500 fluorescence spectrophotometer with wavelength settings of 340 and 380 nm for excitation (alternating) and 510 nm for emission. Active loading of the SR vesicles with Ca²⁺ was started by addition of 100 μM MgATP and 20 μM CaCl₂. Free Ca²⁺ concentration in the cuvette declined with time and reached a steady state within 5 min. At this point, caffeine was added and the changes in fura 2 fluorescence were recorded. For some experiments, 30 μM DP4 was added before the start of Ca²⁺ loading. Calibration of fura 2 signals was carried out with 100–400 nM free Ca²⁺ buffered with 1 mM EGTA in the reaction medium.

Statistics

Data are given as means±S.E.M. for n repeated experiments. To determine the significance of the difference between mean values, Student's unpaired t test was applied.

RESULTS

Protein compositions and the RyR1 content in the SR vesicles isolated from normal and MHS pigs

The protein compositions of SR vesicles isolated from normal and MHS pig skeletal muscles are shown in Figure 1

. Both SR preparations show similar protein compositions in the Coomassie Brilliant Blue-stained SDS/polyacrylamide gel (Figure 1

A). Western blots with the isoform-specific antibodies show that these SR preparations contain comparable amounts of RyR1 and FKBP12, an accessory protein of RyR1 (Figure 1

B). There was no detectable RyR3 (Figure 1

B). Fractions of active channel in the SR vesicles were determined by Scatchard plot analysis of [³H]ryanodine binding. The B_max of the MHS vesicles (16.0±4.6 pmol/mg of protein) was comparable with that of the normal vesicles (17.1±1.1 pmol/mg of protein) (Figure 1

C), indicating that the two SR preparations contain very similar amounts of active RyR1 channels. However, the K_d for [³H]ryanodine was 3-fold smaller (4.3±0.4 nM) in MHS SR than in normal SR (11.8±1.8 nM), indicating that the affinity of ryanodine binding is significantly higher in MHS pigs than in normal pigs.

Figure 1

Protein compositions and the RyR1 content in SR vesicles isolated from normal and MHS pigs

Removal of suppression in RyR1_MHS as shown in the [³H]ryanodine binding assay

Figure 2

shows the Ca²⁺-dependence of the [³H]ryanodine binding to the SR vesicles from normal and MHS pig skeletal muscle. The activity is expressed as B/B_max, in which the ryanodine binding values (B) were corrected for the maximum number of binding sites (B_max), thus reflecting the apparent averaged activity of the individual channels (Figure 2

A). The B/B_max value of RyR1 in normal SR (RyR1_N) at the optimum Ca²⁺ (0.023±0.002; n=3) was comparable with the values from bovine and rabbit skeletal muscle SR vesicles under similar conditions [21,22], suggesting that RyR1_N is suppressed to the same extent as those of the other mammalian species. RyR1 in MHS SR (RyR1_MHS) showed 8-fold greater magnitude of [³H]ryanodine binding than RyR1_N at all Ca²⁺ concentrations examined (B/B_max=0.18±0.02; n=3). As shown in the normalized plot (percentage of the peak value), both RyR1s show almost identical Ca²⁺-dependence in the activating range of Ca²⁺: the K_d values for Ca²⁺ of the Ca²⁺ activating site (K_A,Ca) were 2.5±0.4 μM and 2.0±0.3 μM for RyR1_N and RyR1_MHS respectively (n=3). In the inhibitory concentration range, RyR1_MHS showed 2-fold lower affinity than RyR1_N: K_d values for Ca²⁺ of the Ca²⁺-inactivating site (K_I,Ca) were 0.17±0.03 mM and 0.35±0.06 mM (n=3, P<0.05) for RyR1_N and RyR1_MHS respectively (Figure 2

B).

Figure 2

Ca²⁺-dependence of the [³H]ryanodine binding activity of RyR1_N and RyR1_MHS

Mg²⁺ is known to inhibit the RyR1 channel by two distinct mechanisms: it acts as a competitive antagonist for the Ca²⁺-activating site and as an agonist for the Ca²⁺-inactivating site [25,28,29]. There was no substantial difference in Mg²⁺ inhibition between RyR1_N and RyR1_MHS at higher Ca²⁺ (110 μM) where Mg²⁺ acts exclusively as an agonist for the to Ca²⁺-inactivation site (Figure 3

A, circles): K_d for Mg²⁺ of the Ca²⁺-inactivation site (K_I,Mg) was estimated to be 0.26±0.04 mM and 0.30±0.06 mM for RyR1_N and RyR1_MHS respectively. On the other hand, there was a slight reduction in the Mg²⁺ inhibition of RyR1_MHS at lower Ca²⁺ (4.2 μM) where the inhibitory effect of Mg²⁺ at the Ca²⁺-activation site becomes more involved (Figure 3

A, triangles). K_d for Mg²⁺ of the Ca²⁺-activation site (K_A,Mg) of RyR1_MHS (0.40±0.02 mM; n=3) was significantly (P<0.05) greater than that of RyR1_N (0.21±0.02 mM; n=3), indicating that Mg²⁺-sensitivity for the Ca²⁺-activation site is somehow reduced in RyR1_MHS. There was no appreciable difference between RyR1_N and RyR1_MHS in the sensitivity to the agonist AMPPCP, a non-hydrolysable analogue of ATP: EC₅₀ values were ~0.3 mM for both SR preparations (Figure 3

B). Taken together, these results indicate that the gain of the Ca²⁺-dependent activation of [³H]ryanodine binding is considerably increased in RyR1_MHS without substantial alterations in sensitivity to the CICR ligands. Since the reduced gain of CICR activity is the sign of a suppressed Ca²⁺ channel [21,22], these results suggest that suppression is largely impaired in the RyR1_MHS.

Figure 3

Effects of Mg²⁺ and AMPPCP on the [³H]ryanodine binding of RyR1_N and RyR1_MHS

Unaltered regulation by FKBP12 in RyR1_MHS

We showed previously that suppression of the RyR1 channel is exerted partly by FKBP12 and partly by some mechanisms involving the interdomain interaction [21,22]. FKBP12 is thought to stabilize a closed state of the RyR channel [30] and accounts for ~30% of the suppression [21]. Therefore we investigated regulation of RyR1_N and RyR1_MHS by FKBP12. As shown in Figure 4

(A), comparable amounts of FKBP12 were co-precipitated with RyR1_N and RyR1_MHS, indicating that the RyR1_MHS retains capability to bind FKBP12. Furthermore, 10 μM FK506, which dissociated the bound FKBP12 from RyR1 (Figure 4

A), increased the [³H]ryanodine binding of RyR1_N and RyR1_MHS to almost the same extent (1.9- and 1.8-fold for RyR1_N and RyR1_MHS respectively) (Figure 4

B). Thus we can exclude the possibility that the FKBP12-mediated regulation might be involved in the channel stimulation seen in the RyR1_MHS pigs.

Figure 4

Unaltered regulation by FKBP12 in RyR1_MHS

Differential effects of domain peptides on RyR1_N and RyR1_MHS

The involvement of the interdomain interaction in the impaired suppression of RyR1_MHS was examined using the domain peptide approach [14,22]. In the interdomain interaction hypothesis, the two domains (regions 1 and 2) of RyR1 should interact with each other to stabilize the closed state of the channel, and MH mutation in either domain should weaken the interaction, resulting in activation of the Ca²⁺ release channel. Similar activation can be produced by an exogenous domain peptide (e.g. DP4) which is a part of the mating domain and is reasonably hypothesized to competitively interfere with the interdomain interaction [13]. Thus, if the impaired suppression seen in the RyR1_MHS is caused by the weakened interdomain interaction, we expect that the addition of such domain peptides will produce significant activation in RyR1_N, but will produce little or no activation in RyR1_MHS, because the interaction has already been weakened in the latter. The most effective way to test the physiological significance and specificity of the domain peptide is to introduce an MH mutation into the peptide (e.g. DP4-mut). The mutation should weaken or abolish the ability of the peptide to interfere with the interdomain interaction (cf. the hypothesis), and the mutated peptide has little or no activation effect [13].

The results of this test are shown in Figure 5

. As can be seen, DP4 increased the [³H]ryanodine binding to RyR1_N in a concentration-dependent manner and reached a plateau at approx. 300 μM with the maximal enhancement of 7-fold (from 0.019±0.002 to 0.14±0.02; n=4). DP4-mut produced only slight activation (1.9-fold, from 0.019±0.002 to 0.036±0.003; n=3). These results are consistent with previous reports with rabbit [14] and bovine [22] skeletal muscle SR vesicles. However, the addition of DP4 to RyR1_MHS produced only a very small increase of the ryanodine-binding activity with a peak value of 1.6-fold (from 0.18±0.02 to 0.28±0.03 at 30 μM; n=4), which is comparable with a negligible extent of activation by DP4-mut (1.3-fold, from 0.18±0.02 to 0.23±0.02 at 100 μM; n=3). Thus DP4 had only a little additional effect on RyR1_MHS, in which the suppression had already been removed.

Figure 5

Effects of DP4 and DP4-mut on [³H]ryanodine binding to RyR1_N and RyR1_MHS

Effects of domain peptides on single Ca²⁺ release channel currents of normal and MHS RyR1 channels

Single Ca²⁺ channel currents through the RyR1 were recorded in symmetrical solutions containing 250 mM caesium methane-sulfonate, 20 mM Hepes/Tris, pH 6.8, and 30 μM free Ca²⁺ at a holding potential of −40 mV (Figure 6

). The RyR1_N channel displayed low P_o under control conditions and DP4 increased P_o in a concentration-dependent manner; the P_o value at 30 μM DP4 was approx. 6-fold higher than the control level (Figure 6

A, left). In contrast, the P_o of the RyR1_MHS channel was already 7.4-fold higher than the control level of RyR1_N even in the absence of DP4, and addition of DP4 (10 and 30 μM) produced virtually no further increase in P_o (Figure 6

A, right). A summary of these experiments is presented in Figure 6

(B). The RyR1_MHS channel showed nearly 7-fold higher P_o (0.20±0.03; n=10) than RyR1_N channel (0.030±0.006; n=10) in the absence of DP4, but the difference became smaller in the presence of 30 μM DP4 (P_o=0.14±0.03 and 0.22±0.04 for RyR1_N and RyR1_MHS respectively; n=4). DP4-mut (50 μM) produced no activating effect on either RyR1_N (P_o=0.055±0.011; n=5) or RyR1_MHS (P_o=0.17±0.02; n=5) (Figure 6

Figure 6

Single Ca²⁺ release channel currents through RyR1_N and RyR1_MHS and the effect of DP4

Effects of domain peptides on caffeine-induced Ca²⁺ release from normal and MHS SR vesicles

Ca²⁺ release from the isolated SR vesicles was fluorimetrically monitored using fura 2 as a fluorescent Ca²⁺ probe [22]. The SR vesicles were actively loaded with Ca²⁺ using MgATP in a solution containing 0.17 M KCl and 1 mM free Mg²⁺, and Ca²⁺ release was induced by caffeine. With normal SR vesicles, 5 mM caffeine induced a small Ca²⁺ release (Figure 7

A, left-hand panel). Addition of 30 μM DP4 at the onset of Ca²⁺ loading greatly increased the subsequent Ca²⁺ release. With MHS SR vesicles, in contrast, Ca²⁺ release by 5 mM caffeine was greater than that with normal SR, but was not increased substantially by 30 μM DP4 (Figure 7

A, right-hand panel). The Ca²⁺ release data obtained at various concentrations of caffeine are depicted in Figure 7

(B). DP4 increased the apparent affinity of the normal SR to caffeine; the EC₅₀ of caffeine was changed from ~10 mM to ~3 mM using 30 μM DP4 (Figure 7

B, left-hand panel). This is consistent with the results from bovine SR vesicles [22]. In contrast, 30 μM DP4-mut had no effect on the caffeine-induced Ca²⁺ release (Figure 7

B). In the MHS SR, the sensitivity of Ca²⁺ release to caffeine was much higher (EC₅₀ ~5 mM) than the normal SR, in agreement with a previous report [10] (Figure 7

B, right-hand panel). The sensitivity, however, remained virtually unchanged by the addition of 30 μM DP4 or 30 μM DP4-mut.

Figure 7

Caffeine-induced Ca²⁺ release from the isolated SR vesicles and the effect of DP4

DISCUSSION

Our previous studies demonstrated that Ca²⁺-dependent [³H]ryanodine binding was much lower in RyR1 than in RyR3 in the SR without change in their Ca²⁺ dependences, which was referred to as suppression [20–22]. This finding would be along the same lines as the effect of an adenine nucleotide on CICR, where the agent increased the rate of CICR at any given Ca²⁺ concentration without major change in the Ca²⁺ sensitivity [29]. These findings indicate that occupation by Ca²⁺ of the Ca²⁺ sites may be a necessary but not a sufficient condition for Ca²⁺ release, and necessitate the introduction of the concept of gain or ‘attenuating coefficient’ besides the occupation of the Ca²⁺ sites. We proposed a hypothesis that the gain or the attenuating coefficient is mainly regulated by the interdomain interaction between region 1 and region 2 within RyR 1 [30]. Therefore we could paraphrase the previous results [30–32] as follows: the attenuating coefficient for RyR1 in the SR membrane is 1/7–1/8, whereas it is unity for RyR3. Using MHS pigs with the Arg⁶¹⁵→Cys mutation in RyR1 in the present study, we showed that the attenuating factor was near to unity with the mutated RyR1 in the SR (Figure 2

). We advanced further our hypothesis that aberration in the interdomain interaction may be the main causes of channel dysfunctions seen in RyR1-linked muscle diseases such as MH.

Normal suppression is impaired in the RyR1 channels of the MHS pig model

Extensive studies have been carried out on the MHS pig model, and a considerable amount of information has been accumulated in the literature concerning the altered properties of RyR1 in MH. It is widely recognized that there is a massive increase in the CICR activity in the RyR1_MHS channel, as shown using various types of assay, such as Ca²⁺ release experiments with skinned fibres [33] or isolated SR vesicles [34], [³H]ryanodine binding assay [31,32] and single-channel recordings [35] (for a review, see also [10]). These results may be consistent with the hypothesis that defectiveness in the channel suppression mechanism is a causative mechanism of abnormal activation of the RyR1_MHS channel. Some results, however, claimed a different mechanism: a reduced sensitivity to Ca²⁺/Mg²⁺ inhibition. This hypothesis was based on the finding that RyR1_MHS is less sensitive to Ca²⁺ inactivation or Mg²⁺ inhibition than is RyR1_N [36–40]. The extent of reduction in the Mg²⁺-sensitivity was in the range 1.5–3-fold in these studies. We also found in the present study that there is a 2-fold reduction in the apparent affinity for Ca²⁺ of the Ca²⁺-inactivation site (Figure 2

B) and for Mg²⁺ of the Ca²⁺-activation site (Figure 3

A). However, the magnitude of the change in the Ca²⁺- or Mg²⁺-sensitivity is too small to explain the increase in the CICR (8-fold) (Figure 2

A). Thus it appears that the reduction in Ca²⁺/Mg²⁺-sensitivity may contribute little to the development of the pig MH phenotype.

However, there are controversial reports that no such increase in the CICR activity was observed in RyR1_MHS channels of the pig model [37,40,41]. This reported claim is at least partly due to a higher pH used in these studies, as mentioned below. The dramatic effect of pH on normal and MHS RyR1 channels was demonstrated by Shomer et al. [35,41]. For instance, single RyR1_MHS channels showed much larger P_o (~0.2) at optimum Ca²⁺ concentrations (~10 μM) than the RyR1_N channel (P_o=~0.05) at pH 6.8, whereas there was virtually no difference between the normal and MHS channels at pH 7.4 (P_o=0.4 for both channels), indicating that the higher pH preferentially activated RyR1_N. Balog et al. [40] reported almost the same peak [³H]ryanodine binding activity at pH 7.4, which contrasts with the previously reported results showing a significant difference between the normal and MHS channels at pH 7.0 [33,34] and the present data at pH 6.8. Thus it seems that higher pH (e.g. pH 7.4) preferentially activates the RyR1_N channels; consequently the difference in the CICR activity between RyR1_N and RyR1_MHS channels becomes undetectable. We have found that such an alkaline pH as pH 7.4 lessened the magnitude of the suppression (T. Murayama, unpublished work). Considering that the intracellular pH in skeletal muscle is estimated to be ~7.0 [42,43] and that metabolic acidosis precedes the muscle contracture in the episode of MH [10], it is quite likely that RyR1_MHS channels are in the non-suppressed state unlike the suppressed RyR1_N. The impaired suppression mechanism in the RyR1_MHS channels will then cause erroneously enhanced CICR and cause dysfunction of Ca²⁺ homoeostasis in MHS pigs.

In human MH, more than 80 mutations have been found in the RyR1 gene [8,9]. An important question is then whether the conclusions deduced here from the particular pig MH mutation can be applied to the other MH mutations. With biopsied muscle fibres, Endo and colleagues [44,45] showed an abnormal enhancement of the CICR activity in MH patients at all of the Ca²⁺ concentrations examined. A similar observation was made in the [³H]ryanodine binding assay with SR vesicles from a MH patient carrying a Gly²⁴³⁴→Arg mutation [46]. Thus it appears that the impaired channel suppression is a general mechanism for the pig and human MH phenotype. Various studies of human MH mutations using cultured cells expressing the mutated RyR1 [12,47,48] have shown the increased sensitivity of MH mutants to caffeine or halothane. Yang et al. [12], in particular, reported that RyR1 channels carrying six human MH mutations show reduced Ca²⁺ inactivation and Mg²⁺ inhibition of [³H]ryanodine binding, as also observed in the present study. Unfortunately, only a limited amount of quantitative data are available about the extent of suppression of the channel and the CICR activity of these expressed mutants, probably owing to the limitation in the quantity of the expressed protein. However, the similarity in the phenotype of these expressed mutants suggests that all of these MH mutations share a common mechanism involved in their pathogenic process.

Mechanism of impaired suppression of the RyR1_MHS channel

We have shown recently that the ‘suppression of CICR gain’ is controlled by two independent factors: the RyR1-bound FKBP12 and the tight interdomain interaction within RyR1; the latter mechanism accounts for ~70% of the suppression [21,22]. In the present study, there was no appreciable change in the bound FKBP12 and its regulation in MHS pig skeletal muscle SR (Figure 4

). This excludes the possibility that FKBP12 might be one of the major factors involved in the channel suppression mechanism. On the other hand, there is a clear difference in the effect of DP4 on RyR1_N and RyR1_MHS (Figures 5–7

), indicative of the major contribution of the altered interdomain interaction to the mechanism of the impaired suppression in the RyR1_MHS channel.

An increasing body of evidence supports the interdomain interaction hypothesis that the two domains of RyR1 harbouring many of the reported MH mutations, the N-terminal domain (region 1) and the central domain (region 2), interact with each other, and that tight interaction stabilizes the closed state of the Ca²⁺ channel and weakened interaction destabilizes the channel. Domain peptides that bind specifically to these domains produced channel destabilization effects as shown in several reports [14–17,22]. For example, DP4 that corresponds to the Leu²⁴⁴²–Pro²⁴⁷⁷ segment of region 2, binds with the N-terminal portion of region 1 [18]. This causes local conformational changes in RyR1 [19], unzips the interaction between regions 1 and 2 [19] and activates the Ca²⁺ release channel [15,16,22,49]. Furthermore, an antibody raised against DP4 was found to produce the same effects as DP4 (domain unzipping and channel activation) by reacting with its epitope located in region 2 [17]. These findings strongly support the hypothesis that the RyR Ca²⁺ channels are regulated in fact by mediation of the interaction between region 1 and region 2, and channel activation (i.e. removal of suppression or impaired suppression) by DP4 is caused by the effect of the peptide to interfere with the domain–domain interaction.

According to the interdomain-interaction hypothesis, MH mutation in either of these domains will weaken the interdomain interaction and will destabilize the channel. In fact, DP4-mut, a peptide carrying an Arg²⁴⁵⁸→Cys MH mutation in DP4, produced no activating effect on the RyR channel, presumably due to the reduced or lost ability to interfere with the domain–domain interaction [14,19]. However, this hypothesis has not yet been tested using an actual disease model. In the present study, we demonstrated that DP4 greatly activated RyR1_N, but produced a little or no activation of RyR1_MHS, as shown in the [³H]ryanodine binding assay (Figure 5

), single-channel recordings (Figure 6

) and Ca²⁺ release measurements (Figure 7

). These findings well fit the hypothesis that the RyR1_MHS channel is already activated by the weakened interdomain interaction. Furthermore, the level activated by DP4 in RyR1_N was comparable with that in RyR1_MHS without DP4, indicating that addition of DP4 to RyR1_N could experimentally mimic the phenotype of RyR1_MHS. The results of the present study provide the first direct evidence that the weakened interdomain interaction induced by a mutation in region 1 is the primary cause for the impaired suppression in MH.

It should also be noted that the effectiveness of DP4 varied with the type of measurements: more potent on single-channel recordings than in the [³H]ryanodine binding assay. The reason for this remains unclear, but it is suggested that the accessibility of the peptide to its reactive site may have varied depending on the assay conditions.

It is of interest to know whether affected interdomain interaction can explain the human MH phenotype. An Arg⁶¹⁴→Cys mutation, equivalent to Arg⁶¹⁵→Cys in MHS pigs, has also been found in humans [8]. A recent study with the domain peptides demonstrates that MH mutations within the DP4 peptide (Ile²⁴⁵³→Thr, Arg²⁴⁵⁴→Cys, Arg²⁴⁵⁸→Cys and Arg²⁴⁵⁸→His) reduce its activating effect on the RyR1 channels [50]. Thus the affected interdomain interaction might also be applicable to some human MH mutations. Several human MH mutations have also been found in the C-terminus region (region 3), where many mutations for CCD (central core disease) as well as MH are reported [51]. We tentatively propose that the information concerning the changes in the mode of interaction between region 1 and region 2 (e.g. weakening of the interaction) is transmitted to the transmembrane channel-forming segments by mediation of some regulatory domains, such as region 3. Both the functional and structural studies of the RyR1 channels with different MH mutations will help us to understand better the mechanism of dysfunction of Ca²⁺ release and the postulated involvement of the affected interdomain interaction in the mechanism of pathogenesis of human MH.

Acknowledgments

We thank Dr Renne C. Lu, Dr Paul Leavis, David Schrier and Elizabeth Gowell for synthesis and purification of the peptides. This work was supported in part by Grant-in-Aid for Scientific Research 17590227 (to T.M.) from JSPS (Japan Society for the Promotion of Science), and by NIH (National Institutes of Health) Grants AR 16922 (N.I.) from NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases), and HL072841 (N.I.) from NHLBI (National Heart, Lung, and Blood Institute).

References

1. Meissner G. Ryanodine receptor/Ca²⁺ release channels and their regulation by endogenous effectors. Annu. Rev. Physiol. 1994;56:485–508. [PubMed]

2. Ogawa Y. Role of ryanodine receptors. Crit. Rev. Biochem. Mol. Biol. 1994;29:229–274. [PubMed]

3. Rios E., Pizarro G. Voltage sensor of excitation–contraction coupling in skeletal muscle. Physiol. Rev. 1991;71:849–908. [PubMed]

4. Schneider M. F. Control of calcium release in functioning skeletal muscle fibers. Annu. Rev. Physiol. 1994;56:463–484. [PubMed]

5. Endo M. Calcium release from the sarcoplasmic reticulum. Physiol. Rev. 1977;57:71–108. [PubMed]

6. Ogawa Y., Murayama T., Kurebayashi N. Ryanodine receptor isoforms of non-mammalian skeletal muscle. Front. Biosci. 2002;7:d1184–d1194. [PubMed]

7. Murayama T., Ogawa Y. Roles of two ryanodine receptor isoforms coexisting in skeletal muscle. Trends Cardiovasc. Med. 2002;12:305–311. [PubMed]

8. McCarthy T. V., Quane K. A., Lynch P. J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum. Mutat. 2000;15:410–417. [PubMed]

9. Jurkat-Rott K., McCarthy T., Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve. 2000;23:4–17. [PubMed]

10. Mickelson J. R., Louis C. F. Malignant hyperthermia: excitation–contraction coupling, Ca²⁺ release channel, and cell Ca²⁺ regulation defects. Physiol. Rev. 1996;76:537–592. [PubMed]

11. Melzer W., Dietze B. Malignant hyperthermia and excitation–contraction coupling. Acta Physiol. Scand. 2001;171:367–378. [PubMed]

12. Yang T., Ta T. A., Pessah I. N., Allen P. D. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation–contraction coupling. J. Biol. Chem. 2003;278:25722–25730. [PubMed]

13. Ikemoto N., Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front. Biosci. 2002;7:d671–d683. [PubMed]

14. Yamamoto T., El-Hayek R., Ikemoto N. Postulated role of interdomain interaction within the ryanodine receptor in Ca²⁺ channel regulation. J. Biol. Chem. 2000;275:11618–11625. [PubMed]

15. Lamb G. D., Posterino G. S., Yamamoto T., Ikemoto N. Effects of a domain peptide of the ryanodine receptor on Ca²⁺ release in skinned skeletal muscle fibers. Am. J. Physiol. Cell Physiol. 2001;281:C207–C214. [PubMed]

16. Shtifman A., Ward C. W., Yamamoto T., Wang J., Olbinski B., Valdivia H. H., Ikemoto N., Schneider M. F. Interdomain interactions within ryanodine receptors regulate Ca²⁺ spark frequency in skeletal muscle. J. Gen. Physiol. 2002;119:15–32. [PubMed]

17. Kobayashi S., Yamamoto T., Parness J., Ikemoto N. Antibody probe study of Ca²⁺ channel regulation by interdomain interaction within the ryanodine receptor. Biochem. J. 2004;380:561–569. [PubMed]

18. Kobayashi S., Bannister M. L., Gangopadhyay J. P., Hamada T., Parness J., Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J. Biol. Chem. 2005;280:6580–6587. [PubMed]

19. Yamamoto T., Ikemoto N. Spectroscopic monitoring of local conformational changes during the intramolecular domain–domain interaction of the ryanodine receptor. Biochemistry. 2002;41:1492–1501. [PubMed]

20. Murayama T., Ogawa Y. Selectively suppressed Ca²⁺-induced Ca²⁺ release activity of α-ryanodine receptor (α-RyR) in frog skeletal muscle sarcoplasmic reticulum: potential distinct modes in Ca²⁺ release between α- and β-RyR. J. Biol. Chem. 2001;276:2953–2960. [PubMed]

21. Murayama T., Ogawa Y. RyR1 exhibits lower gain of CICR activity than RyR3 in the SR: evidence for selective stabilization of RyR1 channel. Am. J. Physiol. Cell Physiol. 2004;287:C36–C45. [PubMed]

22. Murayama T., Oba T., Kobayashi S., Ikemoto N., Ogawa Y. Postulated role of interdomain interactions within the type 1 ryanodine receptor in the low gain of Ca²⁺-induced Ca²⁺ release activity of mammalian skeletal muscle sarcoplasmic reticulum. Am. J. Physiol. Cell Physiol. 2005;288:C1222–C1230. [PubMed]

23. Murayama T., Ogawa Y. Characterization of type 3 ryanodine receptor (RyR3) of sarcoplasmic reticulum from rabbit skeletal muscles. J. Biol. Chem. 1997;272:24030–24037. [PubMed]

24. Harafuji H., Ogawa Y. Re-examination of the apparent binding constant of ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid with calcium around neutral pH. J. Biochem. 1980;87:1305–1312. [PubMed]

25. Murayama T., Kurebayashi N., Ogawa Y. Role of Mg²⁺ in Ca²⁺-induced Ca²⁺ release through ryanodine receptors of frog skeletal muscle: modulations by adenine nucleotides and caffeine. Biophys. J. 2000;78:1810–1824. [PubMed]

26. Oba T., Murayama T., Ogawa Y. Redox states of type 1 ryanodine receptor alter Ca²⁺ release channel response to modulators. Am. J. Physiol. Cell Physiol. 2002;282:C684–C692. [PubMed]

27. Oba T., Maeno Y. Acetaldehyde alters Ca²⁺-release channel gating and muscle contraction in a dose-dependent manner. Am. J. Physiol. Cell Physiol. 2004;286:C1188–C1194. [PubMed]

28. Laver D. R., Baynes T. M., Dulhunty A. F. Magnesium inhibition of ryanodine-receptor calcium channels: evidence for two independent mechanisms. J. Membr. Biol. 1997;156:213–229. [PubMed]

29. Meissner G., Rios E., Tripathy A., Pasek D. A. Regulation of skeletal muscle Ca²⁺ release channel (ryanodine receptor) by Ca²⁺ and monovalent cations and anions. J. Biol. Chem. 1997;272:1628–1638. [PubMed]

30. Marks A. R. Cellular functions of immunophilins. Physiol. Rev. 1996;76:631–649. [PubMed]

31. Mickelson J. R., Gallant E. M., Litterer L. A., Johnson K. M., Rempel W. E., Louis C. F. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 1988;263:9310–9315. [PubMed]

32. Hawkes M. J., Nelson T. E., Hamilton S. L. [³H]Ryanodine as a probe of changes in the functional state of the Ca²⁺-release channel in malignant hyperthermia. J. Biol. Chem. 1992;267:6702–6709. [PubMed]

33. Ohta T., Endo M., Nakano T., Morohoshi Y., Wanikawa K., Ohga A. Ca²⁺-induced Ca²⁺ release in malignant hyperthermia-susceptible pig skeletal muscle. Am. J. Physiol. 1989;256:C358–C367. [PubMed]

34. Carrier L., Villaz M., Dupont Y. Abnormal rapid Ca²⁺ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs. Biochim. Biophys. Acta. 1991;1064:175–183. [PubMed]

35. Shomer N. H., Mickelson J. R., Louis C. F. Caffeine stimulation of malignant hyperthermia-susceptible sarcoplasmic reticulum Ca²⁺ release channel. Am. J. Physiol. 1994;267:C1253–C1261. [PubMed]

36. Mickelson J. R., Litterer L. A., Jacobson B. A., Louis C. F. Stimulation and inhibition of [³H]ryanodine binding to sarcoplasmic reticulum from malignant hyperthermia susceptible pigs. Arch. Biochem. Biophys. 1990;278:251–257. [PubMed]

37. Fill M., Coronado R., Mickelson J. R., Vilven J., Ma J. J., Jacobson B. A., Louis C. F. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys. J. 1990;57:471–475. [PubMed]

38. Laver D. R., Owen V. J., Junankar P. R., Taske N. L., Dulhunty A. F., Lamb G. D. Reduced inhibitory effect of Mg²⁺ on ryanodine receptor-Ca²⁺ release channels in malignant hyperthermia. Biophys. J. 1997;73:1913–1924. [PubMed]

39. Owen V. J., Taske N. L., Lamb G. D. Reduced Mg²⁺ inhibition of Ca²⁺ release in muscle fibers of pigs susceptible to malignant hyperthermia. Am. J. Physiol. 1997;272:C203–C211. [PubMed]

40. Balog E. M., Fruen B. R., Shomer N. H., Louis C. F. Divergent effects of the malignant hyperthermia-susceptible Arg⁶¹⁵→Cys mutation on the Ca²⁺ and Mg²⁺ dependence of the RyR1. Biophys. J. 2001;81:2050–2058. [PubMed]

41. Shomer N. H., Louis C. F., Fill M., Litterer L. A., Mickelson J. R. Reconstitution of abnormalities in the malignant hyperthermia-susceptible pig ryanodine receptor. Am. J. Physiol. 1993;264:C125–C135. [PubMed]

42. Bittar E. E. Washington, DC: Butterworth Inc.; 1964. Cell pH.

43. Hagberg H., Larsson S., Haljamae H. A new design of double-barrelled microelectrodes for intracellular pH-measurement in vivo. Acta Physiol. Scand. 1983;118:149–153. [PubMed]

44. Endo M., Yagi S., Ishizuka T., Horiuti K., Koga Y., Amaha K. Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomed. Res. 1983;4:83–92.

45. Kawana Y., Iino M., Horiuti K., Matsumura N., Ohta T., Matsui K., Endo M. Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed. Res. 1992;13:287–297.

46. Richter M., Schleithoff L., Deufel T., Lehmann-Horn F., Herrmann-Frank A. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle. J. Biol. Chem. 1997;272:5256–5260. [PubMed]

47. Tong J., Oyamada H., Demaurex N., Grinstein S., McCarthy T. V., MacLennan D. H. Caffeine and halothane sensitivity of intracellular Ca²⁺ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J. Biol. Chem. 1997;272:26332–26339. [PubMed]

48. Dirksen R. T., Avila G. Distinct effects on Ca²⁺ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys. J. 2004;87:3193–3204. [PubMed]

49. Yamamoto T., Ikemoto N. Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem. Biophys. Res. Commun. 2002;291:1102–1108. [PubMed]

50. Bannister M. L., Hamada T., Murayama T., Harvey P. J., Casarotto M. G., Dulhunty A. F., Ikemoto N. Malignant hyperthermia mutation sites in the Leu²⁴⁴²–Pro²⁴⁷⁷ (DP4) region of RyR1 are clustered in a structurally and functionally definable area. Biochem. J. 2007;401:333–339. [PubMed]

51. Dirksen R. T., Avila G. Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca²⁺ release channels? Trends Cardiovasc. Med. 2002;12:189–197. [PubMed]

Formats:

PubMed articles by these authors

PubMed related articles

Recent Activity

Links

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information